ZYUS Life Sciences Receives United States Patent No. 11,963,943 Covering Pain Management

ZYUS Life Sciences Corporation (the "Company") (TSX-V: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, announced today that the USPTO issued U.S. Patent No. 11,963,943, entitled FORMULATION FOR PAIN MANAGEMENT on today's date. The patent, held by ZYUS' wholly owned subsidiary, ZYUS Life Sciences Inc., is based on International Patent Application No. PCT/CA2020/050588 with claims pertaining to ZYUS' lead drug candidate, Trichomylin^® softgel capsules. This marks the seventh issuance of a patent in this patent family, joining other jurisdictions such as Canada, Australia, Israel, India, Korea and South Africa. The issuance of this patent by the USPTO underscores ZYUS' commitment to innovation and dedication to improving patient outcomes through the development of non-opioid-based pharmaceutical solutions as a viable alternative for managing pain.

Intellectual Property Portfolio

ZYUS' intellectual property portfolio contains multiple patent families related to fixed-dose cannabinoid-based formulations for the treatment of pain and a variety of other clinically unmet needs. Including the U.S. patent issued covering its lead drug candidate, Trichomylin^® softgel capsules, ZYUS' intellectual property portfolio, with a focus on novel therapies, currently contains seven issued patents, eleven nonprovisional patent applications that have been filed internationally, four continuation-in-part applications filed in the U.S. and one provisional patent application directed to formulations and treatments.

Trichomylin^® Softgel Capsules Phase 2 Clinical Trial

Trichomylin^® softgel capsules have been formulated with a proprietary fixed-dose combination, specifically designed for the management of chronic pain by delivering a balanced ratio of three cannabinoids ? cannabichromene ("CBC"), cannabidiol ("CBD") and delta-9-tetrahydrocannabinol ("THC"). ZYUS' previously announced Phase 2 Clinical Trial will assess the preliminary efficacy, safety and tolerability of Trichomylin^® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.

"Receiving this patent for the treatment of pain using our non-opioid-based formulation validates our ongoing commitment to innovation and investment in research, marking a pivotal step towards the development of this urgently needed medicine. To our knowledge, this is the first time a U.S. patent has been awarded for a cannabinoid-based fixed-dosed formulation containing CBC, CBD and THC," said Brent Zettl, President and CEO of ZYUS. "Our clinical development program for the Trichomylin^® formulation is well-positioned for success given both the new patent issuance and recently announced Phase 2 Clinical Trial, which aims to demonstrate preliminary efficacy, safety and tolerability of this novel drug candidate. We intend to use the data from our extensive pre-clinical and non-clinical studies, completed Phase 1 Clinical Trial and proposed Phase 2 Clinical Trial to form the basis of an Investigational New Drug application with the U.S. FDA."

About ZYUS Life Sciences Corporation

ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit www.zyus.com or follow us on X (formerly known as Twitter) @ZYUSCorp.

Cautionary Note Regarding Forward-Looking Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates such as Trichomylin^® softgel capsules, introduce products that act as alternatives to current pain management therapies such as opioids, advance Phase 2 clinical development of Trichomylin^® softgel capsules and Investigational New Drug applications with the US. FDA. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, realize on its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates such as Trichomylin^® softgel capsules, introduce products that act as alternatives to current pain management therapies such as opioids, advance Phase 2 clinical development of Trichomylin^® softgel capsules and file Investigational New Drug applications with the US. FDA are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to advance its clinical research activities and further operations, realize its objectives and obtain regulatory approval of cannabinoid-based pharmaceutical drug product candidates, introduce products that act as alternatives to current pain management therapies such as opioids, advance Phase 2 clinical development of Trichomylin^® softgel capsules or file Investigational New Drug applications with the US. FDA. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.